<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536314</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0115</org_study_id>
    <nct_id>NCT01536314</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Neuropathic Pain by mémantine</brief_title>
  <acronym>MEMANTINE</acronym>
  <official_title>Preventing the Development of Neuropathic Pain Post-mastectomy/Tumorectomy by Pre-emptive or Post-operative Memantine Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr Xavier DURANDO/Dr Marie-Ange MOURET/Dr Christine VILLATTE, Jean-Perrin Cancer Center, Clermont-Ferrand Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2
      weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared
      to placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2
      weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared
      to placebo group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average painful intensity</measure>
    <time_frame>5 days before visit of 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of pain by numerical scale</measure>
    <time_frame>during 15 first days following surgery and to visit of 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average painful</measure>
    <time_frame>on 5 days before visit of 6 months post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analgesic consumption</measure>
    <time_frame>during 3 months after surgery</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Neuropathic Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine EBIXA®</intervention_name>
    <description>The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo : lactose</intervention_name>
    <description>The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old

          -  patient suffering breast cancer with mastectomy/tumorectomy with or within cleaning 2
             weeks after inclusion with or within pre-emptive chemotherapy

        Exclusion Criteria:

          -  Against-indication at memantine administration : hypersensitivity at active substance
             or excipients, hypertension, antecedent cerebrovascular accident, severe cardiac
             insufficiency

          -  Diabetic patient (Type I and II)

          -  Patient with medical or surgical antecedents

          -  Patient receiving treatment with amantadine, ketamine, dextrometorphan, L-Dopa,
             dopaminergic, anticholinergic agonists, barbiturate, neuroleptic, IMAO, antispastic
             agents, dantrolen or baclofen, phenitoin, cimetidine, ranitidine, procainamide,
             quinidine, quinine, nicotine, hydrochlorothiazide, warfarine

          -  Patient with alcohol addiction

          -  Woman in childbearing age not using effective contraceptive method, pregnant or
             lactating woman

          -  Patient who participated in another clinical trial, located in exclusion period or
             received benefits &gt; 4500 euros during 12 months before the beginning of trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisèle PICKERING</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <last_update_submitted>June 30, 2014</last_update_submitted>
  <last_update_submitted_qc>June 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-emptive administration</keyword>
  <keyword>Post-operative administration</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Memantine</keyword>
  <keyword>Post-mastectomy/tumorectomy</keyword>
  <keyword>Neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

